Born from a McMaster University professor’s idea, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, is being acquired by AstraZeneca for up to $2.4 billion. This acquisition will help develop cancer therapeutics in a more targeted and precise manner for more effective treatment with reduced toxic side effects.
Fusion develops next-generation radioconjugates as precision medicine, bringing much-needed therapies to cancer patients. They became a publicly traded spin-out company of the McMaster-based Centre for Probe Development and Commercialization, a hub of innovation and entrepreneurship that helps convert novel ideas and world-class research into innovations for commercialization.
Fusion also partners with McMaster to train graduate students in the development, testing and use of radiopharmaceuticals to identify and treat cancers, creating a unique training experience.
For more information, visit McMaster University.Â
